Claims for Patent: 10,610,600

Summary for Patent: 10,610,600

Title:	Stabilizing excipients for therapeutic protein formulations
Abstract:	The invention encompasses therapeutic formulations comprising a protein active ingredient and a stabilizing excipient, methods of improving stability in a therapeutic formulation comprising a protein active ingredient by adding a stability-improving amount of a stabilizing excipient to the therapeutic formulation, and methods of reducing adverse infusion-related effects in a patient, comprising administering to a patient in need thereof a therapeutic formulation comprising a protein active ingredient and a stabilizing excipient.
Inventor(s):	Soane; David S. (Palm Beach, FL), Mahoney; Robert P. (Newbury, MA), Wuthrich; Philip (Watertown, MA), Greene; Daniel G. (Belmont, MA)
Assignee:	REFORM BIOLOGIES, LLC (Woburn, MA)
Application Number:	16/354,557
Patent Claims:	1. A therapeutic formulation comprising a therapeutic protein and a stability-improving amount of a polypropylene glycol homopolymer, wherein the polypropylene glycol homopolymer has a number-average molecular weight between about 300 and 5000, and wherein the stability-improving amount of the polypropylene glycol homopolymer is between about 10 and 1000 ppm; and wherein the stability-improving amount is the amount that reduces the degradation of the therapeutic formulation by at least 10% when compared to a control formulation, wherein the control formulation is identical on a dry weight basis to the therapeutic formulation except that it lacks the polypropylene glycol homopolymer. 2. The formulation of claim 1, wherein the formulation contains between about 1 .mu.g/mL and about 1 mg/mL of the therapeutic protein. 3. The formulation of claim 1, wherein the formulation contains at least 100 mg/mL of protein active ingredient. 4. The formulation of claim 1, wherein the therapeutic protein is selected from the group consisting of an antibody, an antibody-drug conjugate, an enzyme, a cytokine, a neurotoxin, a fusion protein, an immunogenic protein, a PEGylated protein, and an antibody fragment. 5. The formulation of claim 1, wherein the polypropylene glycol homopolymer is a linear polymer with at least two hydroxyl groups. 6. The formulation of claim 1, wherein the formulation further comprises a second stabilizing excipient. 7. The formulation of claim 1, further comprising an additional agent selected from the group consisting of preservatives, sugars, polysaccharides, arginine, proline, hyaluronidase, stabilizers, buffers, and a combination thereof. 8. A method of improving the stability of a therapeutic formulation comprising a therapeutic protein the method comprising adding a stability-improving amount of a polypropylene glycol homopolymer to the therapeutic formulation,wherein the polypropylene glycol homopolymer has a number-average molecular weight between about 300 and 5000, wherein the stability-improving of the polypropylene glycol homopolymer is between about 10 and 1000 ppm, and wherein the stability-improving amount is the amount that reduces the degradation of the therapeutic formulation by at least 10% when compared to a control formulation, wherein the control formulation is identical on a dry weight basis to the therapeutic formulation except that it lacks the polypropylene glycol homopolymer. 9. The method of claim 8, wherein the polypropylene glycol homopolymer reduces degradation of the therapeutic formulation by at least 50%, as compared to the control formulation. 10. The therapeutic formulation of claim 1, wherein the formulation further comprises an aqueous medium. 11. The therapeutic formulation of claim 1, wherein the formulation contains between about 10 and about 500 ppm of the polypropylene glycol homopolymer. 12. The therapeutic formulation of claim 11, wherein the formulation contains between about 10 and about 100 ppm of the polypropylene glycol homopolymer. 13. The therapeutic formulation of claim 1, wherein the polypropylene glycol homopolymer has a number-average molecular weight of about 425 Daltons. 14. The therapeutic formulation of claim 1, wherein the formulation does not contain an additional surfactant. 15. The therapeutic formulation of claim 1, wherein the polypropylene glycol homopolymer is added in an amount effective to reduce degradation of the formulation by at least 50%, as compared to the control formulation. 16. The therapeutic formulation of claim 15, wherein the polypropylene glycol homopolymer is added in an amount effective to reduce degradation of the formulation by at least 70%, as compared to the control formulation. 17. The therapeutic formulation of claim 16, wherein the polypropylene glycol homopolymer is added in an amount effective to reduce degradation of the formulation by at least 90%, as compared to the control formulation. 18. The therapeutic formulation of claim 1, wherein the polypropylene glycol homopolymer is added in an amount effective to reduce aggregation or precipitation of the therapeutic protein during a cold storage condition. 19. The therapeutic formulation of claim 1, wherein the polypropylene glycol homopolymer is added in an amount effective to reduce aggregation or precipitation of the therapeutic protein during an elevated storage condition. 20. The therapeutic formulation of claim 1, wherein the therapeutic formulation is resistant to foaming. 21. The therapeutic formulation of claim 1, wherein the therapeutic formulation is resistant to micelle formation. 22. The therapeutic formulation of claim 1, wherein the therapeutic formulation has improved stability as compared to a control formulation when the therapeutic formulation is exposed to a stress condition. 23. The therapeutic formulation of claim 22, wherein the stress condition is selected from the group consisting of agitation stress, exposure to air/water interfaces, contact with plastic, glass, or metal surfaces, filtration, column chromatography separation, viral inactivation, exposure to pH conditions between pH 2 and pH 5, exposure to pH conditions between pH 8 and pH 12, exposure to proteolytic enzymes, exposure to lipase enzymes, and exposure to microbiological contamination. 24. The therapeutic formulation of claim 22, wherein the stress condition is selected from the group consisting of oxidation, hydrolysis, proteolysis, deamidation, disulfide scrambling, photodegradation, and microbial degradation.

Details for Patent 10,610,600

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	May 05, 2004		2039-03-15
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	December 02, 2004		2039-03-15
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	October 26, 2004		2039-03-15
Akorn, Inc.	HYDASE	hyaluronidase	Injection	021716	October 25, 2005		2039-03-15
Glaxosmithkline Biologicals	SHINGRIX	zoster vaccine recombinant, adjuvanted	Injection	125614	October 20, 2017		2039-03-15

International Patent Family for US Patent 10,610,600

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2018013673
United States of America	2020282065
United States of America	2019275159
United States of America	2018015169
United States of America	2018015168